Potentin vitroandin vivoactivity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

(2011) Y. X. Zhu et al.   BLOOD

Novel therapies in MM: from the aspect of preclinical studies

(2011) Teru Hideshima et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells

(2011) T Calimeri et al.   LEUKEMIA

Early and mature endothelial progenitors and VEGFR2+-cells in multiple myeloma: Association with disease characteristics and variation in different cell compartments

(2011) Josefina Udi et al.   LEUKEMIA RESEARCH

Animal models: Towards a myeloma mouse

(2011) Sarah DeWeerdt   NATURE

Skin-cancer stem cells outwitted

(2011) Salvador Aznar Benitah   NATURE

A vascular niche and a VEGF–Nrp1 loop regulate the initiation and stemness of skin tumours

(2011) Benjamin Beck et al.   NATURE

Thymoquinone Inhibits the CXCL12-Induced Chemotaxis of Multiple Myeloma Cells and Increases Their Susceptibility to Fas-Mediated Apoptosis

(2011) Gamal Badr et al.   PLoS One

Targeting the Tumor Microenvironment: Focus on Angiogenesis

(2011) Fengjuan Fan et al.   Journal of Oncology

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo

(2009) Claire M. Edwards et al.   AMERICAN JOURNAL OF HEMATOLOGY

Bortezomib induces canonical nuclear factor- B activation in multiple myeloma cells

(2009) T. Hideshima et al.   BLOOD

Src Tyrosine Kinase Regulates Adhesion and Chemotaxis in Waldenstrom Macroglobulinemia

(2009) H. T. Ngo et al.   CLINICAL CANCER RESEARCH

Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301

(2009) Antonius A. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs

(2009) V Ramakrishnan et al.   ONCOGENE

Secondary Erythrocytosis Produced by the Tyrosine Kinase Inhibitors Sunitinib and Sorafenib

(2008) Doru T. Alexandrescu et al.   JOURNAL OF CLINICAL ONCOLOGY

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

(2008) R A Kyle et al.   LEUKEMIA

The effects of thalidomide on chemotactic migration of multiple myeloma cell lines

(2007) S.-I. FUCHIDA et al.   International Journal of Laboratory Hematology